The development and validation of the pandemic medication-assisted treatment questionnaire for the assessment of pandemic crises impact on medication management and administration for patients with opioid use disorders.  Leventelis C, Katsouli…

Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods. Molfenter T, Jacobson N, Kim JS, Horst J, Kim H, Madden L, Brown R, Haram E, Knudsen HK.  J Subst Use Addic…

USA. DEA Announces Proposed Rules for Permanent Telemedicine Flexibilities DEA extends many telemedicine flexibilities adopted during the COVID-19 PHE with appropriate safeguards  WASHINGTON - Today, the Drug Enforcement Administration announ…

Synthesising evidence of the effects of COVID-19 regulatory changes on methadone treatment for opioid use disorder: implications for policy Krawczyk, Noa et al. The Lancet Public Health, Volume 8, Issue 3, e238 - e246  https://www.thelancet…

Providing Low-barrier Addiction Treatment Via a Telemedicine Consultation Service During the COVID-19 Pandemic in Los Angeles, County: An Assessment 1 Year Later.  Kennedy AJ, George JS, Rossetti G, Brown CO, Ragins K, Dadiomov D, Trotzky-Sirr…

Impact of COVID-19-related regulatory changes on nationwide access to buprenorphine: An interrupted time series design.  Roy PJ, Kim KC, Suda K, Luo J, Wang X, Olejniczak D, Liebschutz JM.  Drug Alcohol Depend Rep. 2023 Mar;6:100135. doi…